Stage IV Melanoma Clinical Trial
Official title:
A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients With Recurrent Inoperable Stage III or Stage IV Melanoma
Verified date | April 2018 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery. Combinations of biological substances in VEGF Trap may be able to carry tumor-killing substances directly to melanoma cells. It may also stop the growth of melanoma by blocking blood flow to the tumor.
Status | Completed |
Enrollment | 41 |
Est. completion date | January 2011 |
Est. primary completion date | January 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility |
Inclusion Criteria: - Histologically confirmed stage III or IV melanoma - Cutaneous, ocular, or mucosal melanoma allowed - Recurrent, inoperable disease - Measurable disease, defined as = 1 unidimensionally measurable lesion = 20 mm by conventional techniques OR = 10 mm by spiral CT scan - No evidence of CNS disease, including primary brain tumor or brain metastases - No brain metastases by MRI or CT scan within the past 4 weeks - ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% - Life expectancy > 3 months - WBC = 3,000/mm³ - Absolute neutrophil count = 1,500/mm³ - Platelet count = 75,000/mm³ - Bilirubin < 1.5 times upper limit of normal (ULN) - AST and ALT = 2.5 times ULN - Creatinine = 1.5 times ULN OR creatinine clearance = 60 mL/min - Urine protein:creatinine ratio < 1 OR urine protein < 500 mg by 24-hour urine collection - PT INR = 1.5 unless on full-dose warfarin - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for = 6 months after completion of study treatment - No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies - No history of allergic reactions attributed to compounds of similar chemical or biological composition to agents used in the study - No serious or nonhealing wound, ulcer, or bone fracture - No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days - No significant traumatic injury within the past 28 days - No clinically significant cardiovascular disease, including any of the following: - Cerebrovascular accident within the past 6 months - Uncontrolled hypertension, defined as blood pressure (BP) > 150/100 mm Hg or systolic BP > 180 mm Hg if diastolic BP < 90 mm Hg within the past 3 months - Myocardial infarction, coronary artery bypass graft, or unstable angina within the past 6 months - New York Heart Association class III-IV congestive heart failure - Serious cardiac arrhythmia requiring medication - Unstable angina pectoris within the past 6 months - Clinically significant peripheral vascular disease within the past 6 months - Pulmonary embolism, deep vein thrombosis, or other thromboembolic event within the past 6 months - No evidence of bleeding diathesis or coagulopathy - No concurrent uncontrolled illness, including, but not limited to any of the following: - Ongoing or active infection - Psychiatric illness or social situation that would preclude study compliance - Recovered from all prior therapy and major surgery - No prior chemotherapy or hormonal therapy - More than 7 days since prior core visceral organ biopsy - More than 4 weeks since prior biologic therapy or radiotherapy - More than 28 days since prior major surgery or open biopsy - No concurrent major surgery - No other concurrent investigational agents - No concurrent combination antiretroviral therapy for HIV-positive patients - Concurrent full-dose warfarin with PT INR > 1.5 allowed provided the following criteria are met: - INR in range (2-3) on a stable dose of oral anticoagulant or low molecular weight heparin - No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate (CR + PR) | Using the RECIST v1.0 criteria for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response = CR + PR.", | Start of treatment to disease progression/recurrence, up to 5 years | |
Primary | 4 Month Progression-free Survival | Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. | 4 months | |
Secondary | Overall Survival | Will be estimated by the Kaplan-Meier method. | From the initial date of treatment to the recorded date of death, assessed up to 5 years | |
Secondary | Number of Participants With Toxicities | The descriptions and grading scales found in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 were utilized for AE grading and reporting. Grade 3 and higher adverse events considered possibly, probably or definitely related to aflibercept are summarized. | Up to 5 years | |
Secondary | Impact of the VEGF Trap Therapy on Laboratory Correlates | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02107755 -
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Withdrawn |
NCT01216787 -
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
|
Phase 2 | |
Active, not recruiting |
NCT01026324 -
Dinaciclib in Treating Patients With Stage III-IV Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT01010984 -
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
|
N/A | |
Completed |
NCT00553306 -
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
Completed |
NCT00019448 -
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03200847 -
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03235245 -
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
|
Phase 2 | |
Terminated |
NCT01875653 -
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
|
Phase 3 | |
Completed |
NCT01748747 -
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
|
Early Phase 1 | |
Terminated |
NCT01316692 -
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT01120275 -
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Terminated |
NCT01166126 -
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
|
Phase 2 | |
Terminated |
NCT01026051 -
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00288041 -
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00072163 -
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
|
Phase 2 | |
Completed |
NCT00074308 -
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
|
Phase 1/Phase 2 |